Search

for
Search:

Did you mean PADI3?

GlossaryPADI3

enzyme crucial for hair shaft formation and maintenance

PADI3 stands for Peptidyl Arginine Deiminase, Type III, an enzyme that plays a crucial role in the formation and maintenance of hair. It modifies certain proteins in hair follicles, which is essential for proper hair shaft formation. Mutations in the PADI3 gene can lead to hair disorders such as uncombable hair syndrome, characterized by dry, frizzy hair that is resistant to being combed flat.

Related Terms

Sort by

Community Join

30 / 1000+ results

community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga

in Technology 8 upvotes 3 months ago

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

community A warning to anyone considering 3rd party sourcing PP405 or its analogs

in Treatment 31 upvotes 1 month ago

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

community P5P supplementation for fin sides.

in Treatment 7 upvotes 4 years ago

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

community PP405 (Everychem 3HP) Anecdotes - Please assemble and share your story

in Chat 107 upvotes 1 month ago

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting

in Chat 30 upvotes 1 month ago

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

community My summation of PP405 - looks promising

in Research/Science 208 upvotes 1 year ago

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

community Il PP405 è molto promettente ma non è l'unico in grado di liberarci dalla iattura

in Research/Science 3 upvotes 7 months ago

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

community SUBE3 for sale in the gray market?

in Chat 5 upvotes 1 year ago

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

community Pp405 any site for buying in Europe

in Product 2 weeks ago

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

community Why doesn't phase 3 of PP405 start straight away?

in Chat 14 upvotes 4 months ago

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

community Pp405 AAD presentation tomorrow - fingers crossed - what to expect?

in Research/Science 84 upvotes 1 month ago

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

community PTD-DBM Update: Q&A With Dr. Kang-Yell Choi

in Treatment 13 upvotes 6 years ago

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

community PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed

in Research/Science 25 upvotes 1 year ago

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

community Oral PTD-DBM available online, worth giving a shot?

in Research/Science 4 upvotes 6 years ago

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

community PP405 Identity Research

in Research 292 upvotes 8 months ago

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy

in Research/Science 10 upvotes 5 years ago

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

community SETIPIPRANT PGE2 GROUP BUY AND PIONEERING HAIR GROWTH

7 upvotes 10 years ago

The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.

community Pp405 phase 2a clinical results

in Research/Science 40 upvotes 10 months ago

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

community VDPHL01 works really quickly .. apparently?

in Research/Science 47 upvotes 1 month ago

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

community Does anyone know of the actual effectiveness of the DP2 inhibitors?

in Question 4 upvotes 8 years ago

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

community Anyone heard of scube3? And other emerging treatments?

in Research/Science 4 upvotes 1 year ago

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.

in Research/Science 73 upvotes 6 months ago

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

community is there any news about pp405 please

in Update 11 upvotes 1 year ago

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

community Pelage are starting phase 3 for PP405 towards the end of 2026

in Chat 180 upvotes 2 months ago

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

community It looks like Pelage are giving hints that PP405 is a game changer

in Chat 246 upvotes 1 month ago

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

community How much do we know about PTD-DBM?

in Question 7 upvotes 7 years ago

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

community The New, Improved CB-03-01/Setipiprant Group Buy

29 upvotes 9 years ago

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy

in Technology 66 upvotes 10 months ago

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

community Pelage PP405: New Hair Growth from Inactive Follicular Units - Phase 2a results at AAD 2026

in Research/Science 1067 upvotes 1 month ago

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

community PP405 Update and My Take on Pelage

in Research/Science 86 upvotes 6 months ago

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.